{"id":"9e4e4af2-68f2-56de-83b5-6e494504cd24","stable_key":"cb41aa31-e26b-5b60-b7e0-e4985fb7aea8:hydroxytyrosol-cardiometabolic-null","predicate":"does_not_significantly_change","statement":"The same one-week trial did not detect significant changes in lipid profile or tested inflammation and oxidation markers.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"bfa3457f-96ca-5d33-9cc5-8699271370ac","mechanism_event_label":"The same one-week trial did not detect significant changes in lipid profile or tested inflammation and oxidation markers.","subject":{"id":"45a7aaec-8acc-5d5a-a014-c483ef5385e2","slug":"hydroxytyrosol","display_name":"Hydroxytyrosol","entity_type_key":"small_molecule"},"object":{"id":"ab484a49-846c-541e-b10e-9f74dc753221","slug":"human-short-term-cardiovascular-surrogate-panel","display_name":"Human lipid, inflammatory and oxidation surrogate-marker panel","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"bfa3457f-96ca-5d33-9cc5-8699271370ac","stable_key":"cb41aa31-e26b-5b60-b7e0-e4985fb7aea8:hydroxytyrosol-cardiometabolic-null-event","event_type":"observed_relationship","label":"The same one-week trial did not detect significant changes in lipid profile or tested inflammation and oxidation markers.","description":"The same one-week trial did not detect significant changes in lipid profile or tested inflammation and oxidation markers.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"45a7aaec-8acc-5d5a-a014-c483ef5385e2","slug":"hydroxytyrosol","display_name":"Hydroxytyrosol","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"ab484a49-846c-541e-b10e-9f74dc753221","slug":"human-short-term-cardiovascular-surrogate-panel","display_name":"Human lipid, inflammatory and oxidation surrogate-marker panel","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"dose","value_text":"5 or 25 mg/day hydroxytyrosol","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"duration","value_text":"1 week","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_access","value_text":"Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"evidence_scope","value_text":"literature_reviewed; model-specific source-derived curation","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Human randomized placebo-controlled trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Short duration and surrogate outcomes limit inference, but the null result should accompany mechanistic claims.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Hydroxytyrosol chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings.","comparator":null,"unit":null,"notes":"","entity":{"slug":"hydroxytyrosol","display_name":"Hydroxytyrosol","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human randomized placebo-controlled trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The same one-week trial did not detect significant changes in lipid profile or tested inflammation and oxidation markers.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"One-week administration of hydroxytyrosol to humans does not activate Phase II enzymes. (2015). https://pubmed.ncbi.nlm.nih.gov/25836918/ DOI: 10.1016/j.phrs.2015.03.018","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"route","value_text":"Oral","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue","value_text":"Cardiovascular surrogate markers","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"ce75108a-3bf7-5812-acab-3f95e9829a66","evidence_kind":"source_excerpt","locator":"Lines 77-86","start_line":77,"end_line":86,"excerpt":"## hydroxytyrosol-cardiometabolic-null\nThe same one-week trial did not detect significant changes in lipid profile or tested inflammation and oxidation markers.\nModel/species: Human randomized placebo-controlled trial\nTissue/system: Cardiovascular surrogate markers\nExposure: 5 or 25 mg/day hydroxytyrosol\nRoute: Oral\nDuration: 1 week\nLimits: Short duration and surrogate outcomes limit inference, but the null result should accompany mechanistic claims.\nPrimary reference: One-week administration of hydroxytyrosol to humans does not activate Phase II enzymes. (2015). https://pubmed.ncbi.nlm.nih.gov/25836918/ DOI: 10.1016/j.phrs.2015.03.018\nAccess: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.","model_system":"Human randomized placebo-controlled trial","directness":"reported_statement","verification_status":"source_derived_draft","notes":"Exact original curation span with primary citation; not a publisher quotation.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"f83cd982-34f0-55d4-8563-eedfb0f009f2","stable_key":"import-cb41aa31-e26b-5b60-b7e0-e4985fb7aea8","title":"Hydroxytyrosol: mechanism of action and interactions (2026-09-20)","document_type":"imported_text","citation_label":"Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text.","file_path":"","sha256":"7677fedffc16af238fc1ace3f88d206dd42b29b163c40b6e69ba6ed2457a3aee","revision_id":"1e0bd617-6834-5a2d-a74e-c058967d99b7","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}